Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM3ICO6)

Drug Name
JNJ-74494550 Drug Info
Synonyms Cusatuzumab
Indication
Disease Entry ICD 11 Status REF
Myelodysplastic syndrome 2A37 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM3ICO6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CD70 antigen (CD27-L) TTNCIE0 CD70_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
CD70 antigen (CD27-L) DTT CD70 5.138 3.35 4.621 2.907
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Myelodysplastic syndrome
ICD Disease Classification 2A37
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
CD70 antigen (CD27-L) DTT CD70 1.53E-09 0.76 2.84
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04264806) A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT). U.S. National Institutes of Health.
2 Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.